摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(1-methylethyl)-3H-quinazoline-4-thione | 13193-53-8

中文名称
——
中文别名
——
英文名称
2-(1-methylethyl)-3H-quinazoline-4-thione
英文别名
2-isopropyl-3H-quinazolin-4-thione;2-isopropyl-3,4-dihydroquinazolin-4-thione;2-(1-methylethyl)-3,4-dihydroquinazolin-4-thione;2-isopropyl-3H-quinazoline-4-thione;2-Isopropyl-3H-chinazolin-4-thion;2-propan-2-yl-1H-quinazoline-4-thione
2-(1-methylethyl)-3H-quinazoline-4-thione化学式
CAS
13193-53-8
化学式
C11H12N2S
mdl
MFCD03713577
分子量
204.296
InChiKey
JQFZNBGEAOFSEC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.272
  • 拓扑面积:
    56.5
  • 氢给体数:
    1
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(1-methylethyl)-3H-quinazoline-4-thione 作用下, 以 乙醇 为溶剂, 反应 3.0h, 以50%的产率得到2-(1-methylethyl)-4-(4-hydrazino)quinazoline
    参考文献:
    名称:
    El-Hashash; Rizk, Egyptian Journal of Chemistry, 2011, vol. 54, # 4, p. 411 - 422
    摘要:
    DOI:
  • 作为产物:
    参考文献:
    名称:
    Phosphodiesterase inhibitory properties of losartan. design and synthesis of new lead compounds
    摘要:
    A 4-centre PDE 4 pharmacophore search has been carried out in several 3D-databases containing compounds belonging to different therapeutic areas. Losartan, an angiotensin-II antagonist, has been identified as a new lead compound for developping PDE 4 inhibitors. New families of compounds derived from losartan has been synthesized and their PDE inhibition has been measured. (C) 1998 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(98)00058-4
点击查看最新优质反应信息

文献信息

  • A Simple Procedure for the Side-Chain Substitution of 2-Alkyl-3<b> <i>H</i> </b>-quinazo­line-4-thiones: Application in Synthesis
    作者:Gamal A. El-Hiti
    DOI:10.1055/s-2004-815923
    日期:——
    Double lithiation of 2-alkyl-3H-quinazoline-4-thiones at nitrogen and at the α-hydrogen of the 2-alkyl group (Me, Et, Pr) has been achieved with n-butyllithium at -78 °C in anhydrous THF under nitrogen. Reactions of the dilithium reagents obtained with various electrophiles (iodomethane, iodoethane, 1-bromobutane, D2O, benzaldehyde, 4-anisaldehyde, butan-2-one, cyclohexanone, benzophenone, phenyl isothiocyanate, tetraisopropylthiuram disulfide) gave the corresponding modified 2-substituted 3H-quinazoline-4-thiones 4-22 in excellent yields.
    2- 烷基-3H-喹唑啉-4-硫醚在氮和 2-烷基(Me、Et、Pr)的δ-氢处与正丁基锂在-78 °C的无水四氢呋喃中在氮条件下实现了双重石化作用。将得到的二锂试剂与各种亲电体(碘甲烷、碘乙烷、1-溴丁烷、D2O、苯甲醛、4-甲氧基苯甲醛、丁-2-酮、环己酮、二苯甲酮、异硫氰酸苯酯、二硫化四异丙基秋兰姆)反应,可以得到相应的改性 2-取代 3H-喹唑啉-4-硫酮 4-22,收率极高。
  • Bogert; Breneman; Hand, Journal of the American Chemical Society, 1903, vol. 25, p. 377
    作者:Bogert、Breneman、Hand
    DOI:——
    日期:——
  • Phosphodiesterase inhibitory properties of losartan. design and synthesis of new lead compounds
    作者:Victor Segarra、M. Isabel Crespo、Ferran Pujol、Jorge Beleta、Teresa Doménech、Montserrat Miralpeix、Jose M. Palacios、Ana Castro、Ana Martinez
    DOI:10.1016/s0960-894x(98)00058-4
    日期:1998.3
    A 4-centre PDE 4 pharmacophore search has been carried out in several 3D-databases containing compounds belonging to different therapeutic areas. Losartan, an angiotensin-II antagonist, has been identified as a new lead compound for developping PDE 4 inhibitors. New families of compounds derived from losartan has been synthesized and their PDE inhibition has been measured. (C) 1998 Elsevier Science Ltd. All rights reserved.
  • [EN] COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION COMME INHIBITEURS D'HDAC6
    申请人:[en]AUGUSTINE THERAPEUTICS
    公开号:WO2023118507A2
    公开(公告)日:2023-06-29
    The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein Y1is a 9- or 10-membered bicyclic heteroaryl, Y2is a 5-membered heteroaryl, Z1is selected from (C=O)-R9, S(O)-R9and S(O2)-R9, L is an alkyl-, cycloalkyl- or heterocycloalkyl-based linker, and R1and R9may be various groups. The present invention further relates to a compound of formula (I) as HDAC6 inhibitor, typically for use in the treatment and/or the prevention of an HDAC6-associated disease, such as cancers, neurodegenerative diseases, neuropathies or cardiovascular diseases.
  • Synthesis and evaluation of quinazoline derivatives as phosphodiesterase 7 inhibitors
    作者:Ana I. Sánchez、Valentín Martínez-Barrasa、Carolina Burgos、Juan J. Vaquero、Julio Alvarez-Builla、Emma Terricabras、Víctor Segarra
    DOI:10.1016/j.bmc.2013.01.067
    日期:2013.4
    The latest scientific findings concerning PDE7 and PDE4 inhibition suggest that selective small-molecule inhibitors of both enzymes could provide a novel approach to treat a variety of immunological diseases. In this context, we describe a new series of quinazoline derivatives from quinazolin-4-thiones which include a substituted biphenyl fragment. Some of these compounds show inhibitory potencies at sub-micromolar levels against the catalytic domain of PDE7. (C) 2013 Elsevier Ltd. All rights reserved.
查看更多